ArticleMicrobiology spectrum2022
Description of a Rare Pyomelanin-Producing Carbapenem-Resistant Acinetobacter baumannii Strain Coharboring Chromosomal OXA-23 and NDM-1.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Genomic and phenotypic characterization of carbapenem-resistant Acinetobacter baumannii isolates from patients and trolleys and their potential connections in an intensive care unit.BMC microbiology · 2026Observational
- Comparative genomic and resistance characterization of ST2 and ST164 carbapenem-resistantMicrobial genomics · 2026Article
- The therapeutic potential of phage pT2784 against ST40-KL47 typeMicrobiology spectrum · 2026Article
- Comparative genomic insights into carbapenem-resistant versus susceptibleFrontiers in cellular and infection microbiology · 2026Article
- Genomic characterisation of extensively drug-resistant Acinetobacter baumannii isolates from a tertiary hospital in Ghana.PloS one · 2026Article
- New resistance threat in difficult-to-treat resistanceEmerging microbes & infections · 2025Article
- Genomic and phenotypic insights into ST164 blaBMC microbiology · 2025Article
- Genomic insights into drug resistance and virulence determinants in rare pyomelanin-producing clinical isolates of Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Phenotypic and Molecular Characterization of Pyomelanin-ProducingMicroorganisms · 2025Article
- Phylogenomic analysis of OXA-23-positive and genetic context of rare NDM-1-producing carbapenem-resistantFrontiers in microbiology · 2025Article
- Longitudinal genomics reveals carbapenem-resistant Acinetobacter baumannii population changes with emergence of highly resistant ST164 clone.Nature communications · 2024Article
- Genomic Insights into and In Vitro Evaluation of Antimicrobial Combination Therapies for Carbapenem-ResistantMedicina (Kaunas, Lithuania) · 2024Article
- Article
- Healthcare Equipment and Personnel Reservoirs of Carbapenem-ResistantMicroorganisms · 2023Article
- Emergence and Evolution of OXA-23-Producing ST46Antibiotics (Basel, Switzerland) · 2023Article
- Genotyping ofAccess microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB), which belonged to global clones 1 (GC1) or 2 (GC2), has been widely reported and become a global threat. However, non-GC1 and non-GC2 CRAB strains are not well-studied, especially for those with rare phenotype. Here, one pyomelanin-producing CRAB strain (A. baumannii DETAB-R21) was isolated from oral swab in the ICU. Antimicrobial susceptibility testing showed it was resistant to carbapenems, ceftazidime, levofloxacin, and ciprofloxacin. DETAB-R21 was ST164
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.